Compare Sanofi SA (SNY) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Upstart Holdings Inc — how do they compare? Sanofi SA trades at $43.63 (market cap $104.83B), while Upstart Holdings Inc trades at $29.15 (market cap $2.76B). The key difference: Sanofi SA is far larger — about 38× Upstart Holdings Inc's market cap, and Sanofi SA pays a 5.5% dividend while Upstart Holdings Inc pays none. Which is the better fit depends on your goals.
| SNY | UPST | |
|---|---|---|
Market Cap | $104.83B | $2.76B |
Sector | Health | Financials |
52-Week High | $52.34 | $84.13 |
52-Week Low | $41.33 | $24.22 |
Enterprise Value | $121.32B | — |
Dividend Yield | 5.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.97, down 1.55% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings of $1.10 per share, beating expectations, and maintains robust profitability with a 71.92% gross margin. Recent FDA approval for Sarclisa's subcutaneous formulation and expanded AI research collaboration with Aqemia highlight ongoing innovation. Cash flow from operations remains healthy at $10.75 billion for 2025, though net cash flow is minimal at $49 million.
SNY presents a balanced investment case with solid fundamentals and analyst support (44% buy ratings), but faces risks from EU antitrust probes and patent expiration concerns for key drug Dupixent. Valuation metrics appear reasonable with P/E of 19.81 and P/B of 1.29. The stock's outlook depends on successful drug pipeline execution and navigating regulatory challenges, with current price levels offering stability near support.
Upstart Holdings trades at $28.68, down 2.81% on the day, with a bearish technical signal but oversold RSI levels. The company reported a net income of $53.60M in 2025, a significant improvement from prior losses, though recent Q1 2026 earnings missed expectations. Revenue growth to $1.02B in 2025 and expanding AI lending platform into auto and home loans highlight operational progress.
The stock presents a recovery opportunity with analyst consensus target of $42.00, but faces risks from volatile earnings, high debt levels, and margin pressure. Investor sentiment is mixed amid ongoing execution challenges in a competitive fintech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
